NCT03589547View on ClinicalTrials.gov

Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 13, 2019

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions
Stage III Non-small-cell Lung Cancer
Interventions
DRUG

Durvalumab

Durvalumab10mg/kg Q2 weeks (+/- 4 days) for a total of 12 months (maximum of 26 treatments total)

RADIATION

SBRT

"SBRT boost will consist of 2 fractions delivered to the primary tumor only, over 1-2 weeks between the first and second treatments with durvalumab.~The dose will consist of 20Gy (2 fractions of 10Gy)~\*3 fractions are allowed for centrally located tumors"

Trial Locations (2)

02903

Rhode Island Hospital, Providence

02906

The Miriam Hospital, Providence

Sponsors

Lead Sponsor

Brown University
All Listed Sponsors
collaborator

Lifespan

OTHER

lead

Brown University

OTHER

NCT03589547 - Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung | Biotech Hunter | Biotech Hunter